ArticleEClinicalMedicine2026

Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304).

Chi Kin Law et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.